NEURENTIS PLC

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

MHA Audit Services LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.”

Group structure

1. NEURENTIS PLC · parent
   1. Neurentis (UK) Limited 100% · UK · pharmaceutical
   2. Neurentis BV 100% · Belgium

Significant events

• “In 2025, Neurentis began the development planning of its lead programme, Quivara™™, toward Phase 3 development in partnership with Viatris, expanded its pipeline to five product candidates including orphan drug designations for rare diseases, and progressed EIS assurance to support UK investor participation.”
• “The company also advanced preparations towards a public listing, selecting advisors, and strengthened collaborations with leading research institutions.”
• “During 2025, we made exceptional strides in broadening our pipeline into the highly attractive field of rare neurological diseases, creating two new drug candidates focused on Progressive Supranuclear Palsy, Perry syndrome, and Multiple System Atrophy.”
• “we continued to drive our lead programme, Quivara™™, closer towards its pivotal Phase 3 trial for Treatment-Resistant Depression. Following our strategic collaboration with Viatris, we held highly productive Joint Development Committee meetings to meticulously plan the development trajectory. Furthermore, we successfully identified and selected an appropriate Contract Research Organisation to execute this crucial Phase 3 trial”
• “we progressed discussions resulting in agreements with two leading research institutions to explore new drugs for neurological disorders.”
• “we actively worked towards a stock market listing, identifying and choosing a suite of expert advisors to guide us through this process. In parallel, we undertook substantial work to secure Enterprise Investment Scheme assurance, filing our application in December 2025. I am delighted to report that, as a post balance sheet event, we received formal assurance from HM Revenue and Customs in February 2026”
• “2025 was a year of strategic acceleration and disciplined pipeline expansion for Neurentis. We successfully executed on our buy and build strategy and delivered tangible progress across our clinical programmes, validating our model and setting the stage for meaningful near term value inflection. In addition to focusing on advancing Quivara™™, we also expanded into the lucrative orphan drug space, and positioned the Company for future capital market activities.”
• “we progressed and deepened our relationships with two leading research institutions. These collaborations are focused on the exploration and development of entirely new drugs for severe neurological disorders.”
• “A major focus of our corporate development work in 2025 was structuring the company to be optimally attractive to both individual and institutional investors. We committed significant time and resource to working towards a future stock market listing.”
• “Concurrently, we engaged extensively with advisors to secure Enterprise Investment Scheme assurance from HM Revenue and Customs. ... We prepared and filed our comprehensive application for this assurance in December 2025, following the year end. In February 2026, we were extremely pleased to receive formal advanced assurance.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

1

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.